title: [Treatment of iron deficiency by a bolus intravenous iron dextran in peritoneal dialysis].
abstract: BACKGROUND
  The main objective of this study is to determine whether a single dose of iron dextran can correct iron deficiency during a period of four months in peritoneal dialysis patients.
  
  
  METHODS
  This was a prospective observational study in peritoneal dialysis patients who had anemia (hemoglobin<11g/dL) and iron deficiency (ferritin<100μg/L and/or transferrin saturation<20%). Patients who were resistant to oral iron or who could not tolerate oral iron were included in the study. At baseline, based on the iron deficiency estimation, a single dose of iron dextran was infused over four hours.
  
  
  RESULTS
  Of 17 patients included, 12 completed the study. The mean iron dose infused was 742±150mg. No clinically significant adverse event was reported during the infusion. Four months after the iron dextran infusion there was a significant increase of the mean hemoglobin level (10.1±0.7g/dl vs 11.4±1.2g/dL, P<0.05), the mean blood ferritin level (66±46mg/L vs 212±121mg/L, P<0.05) and the mean transferrin saturation (14±5% vs 23±8, P<0.05). Four months after the iron infusion 10 patients had a blood ferritin level higher than 100μg/L and a transferrin saturation higher than 20%. There was no significant modification of the erythropoietin dose during the four months period.
  
  
  CONCLUSIONS
  In patients treated by peritoneal dialysis, the anemia due to iron deficiency can be treated by a single infusion of iron dextran for a period of four months.
authors.affiliation: Service de néphrologie, CHU Clémenceau, avenue G.-Clémenceau, 14033 Caen cedex, France.
authors.forename: Maxence
authors.initials: M
authors.lastname: Ficheux
authors.forename: Pascale
authors.initials: P
authors.lastname: Cuny
authors.forename: Angélique
authors.initials: A
authors.lastname: Lecouf
authors.forename: Jean-Philippe
authors.initials: JP
authors.lastname: Ryckelynck
authors.forename: Bruno
authors.initials: B
authors.lastname: Hurault de Ligny
authors.forename: Thierry
authors.initials: T
authors.lastname: Lobbedez
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000465:Algorithms; D018798:Anemia, Iron-Deficiency / Q000097:blood* / Q000188:drug therapy* / Q000209:etiology; D015415:Biomarkers / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D005293:Ferritins / Q000097:blood*; D006397:Hematinics / Q000008:administration & dosage*; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D007262:Infusions, Intravenous; D007505:Iron-Dextran Complex / Q000008:administration & dosage*; D007676:Kidney Failure, Chronic / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D010530:Peritoneal Dialysis / Q000009:adverse effects*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D015415:Biomarkers; D006397:Hematinics; D006454:Hemoglobins; D007505:Iron-Dextran Complex; D005293:Ferritins